Reza Bayat Mokhtari

Dr. Reza Bayat Mokhtari


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Reza Bayat MokhtariReza Bayat Mokhtari
Reza Bayat Mokhtari
THTina S. Homayouni
Tina S. Homayouni
NBNarges Baluch
Narges Baluch
EMEvgeniya Morgatskaya
Evgeniya Morgatskaya
SKSushil Kumar
Sushil Kumar
HYHerman Yeger
Herman Yeger
Combination therapy in combating cancer

23 July 2017 in Journal of Cell Communication and Signaling
Verified
Journal Article
Closed access
PDF file
Reza Bayat MokhtariReza Bayat Mokhtari
Reza Bayat Mokhtari
NBNarges Baluch
Narges Baluch
THTina S. Homayouni
Tina S. Homayouni
EMEvgeniya Morgatskaya
Evgeniya Morgatskaya
SKSushil Kumar
Sushil Kumar
HYHerman Yeger
Herman Yeger

18 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Reza Bayat MokhtariReza Bayat Mokhtari
Reza Bayat Mokhtari
MSManpreet Sambi
Manpreet Sambi
BQBessi Qorri
Bessi Qorri
NBNarges Baluch
Narges Baluch
NANeda Ashayeri
Neda Ashayeri
Myron R. SzewczukMyron R. Szewczuk
Myron R. Szewczuk
Cancer immunotherapy harnesses the immune system by targeting tumor cells that express antigens recognized by immune system cells, thus leading to tumor rejection. These tumor-associated antigens include tumor-specific shared antigens, differentiation antigens, protein products of mutated genes and rearrangements unique to tumor cells, overexpressed tissue-specific antigens, and exogenous viral proteins. However, the development of effective therapeutic approaches has proven difficult, mainly because these tumor antigens are shielded, and cells primarily express self-derived antigens. Despite innovative and notable advances in immunotherapy, challenges associated with variable patient response rates and efficacy on select tumors minimize the overall effectiveness of immunotherapy. Variations observed in response rates to immunotherapy are due to multiple factors, including adaptative resistance, competency, and a diversity of individual immune systems, including cancer stem cells in the tumor microenvironment, composition of the gut microbiota, and broad limitations of current immunotherapeutic approaches. New approaches are positioned to improve the immune response and increase the efficacy of immunotherapies, highlighting the challenges that the current global COVID-19 pandemic places on the present state of immunotherapy.

10 September 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
Reza Bayat MokhtariReza Bayat Mokhtari
Reza Bayat Mokhtari
MSManpreet Sambi
Manpreet Sambi
FSFaezeh Sheakri
Faezeh Sheakri
KSKosar Satari
Kosar Satari
RGRoya Ghafoury
Roya Ghafoury
Sayan ChakrabortySayan Chakraborty
Sayan Chakraborty
Cancer remains a major cause of mortality worldwide, driving ongoing innovation in therapeutic strategies. Immunotherapy has transformed cancer care by leveraging the immune system to target tumors, but its effectiveness is limited by tumor heterogeneity, immune resistance, and unpredictable toxicities. Moreover, the absence of robust biomarkers to predict therapeutic response and manage adverse effects remains a significant challenge. Recent advances in biomarker discovery, including liquid biopsy technologies and gut microbiota profiling, are enhancing the precision of immunotherapy and enabling more personalized cancer management. Here, we present a Comprehensive Oncological Biomarker Framework that integrates genetic and molecular testing, imaging, histopathology, multi-omics, and liquid biopsy to generate a molecular fingerprint for each patient. This holistic approach supports individualized diagnosis, prognosis, treatment selection, and response monitoring. Incorporating emerging biomarkers, such as microbiome signatures, further refines patient stratification, guiding the optimization of therapy. By uniting molecular insights with clinical and social factors, this framework aims to address tumor heterogeneity and immune evasion, ultimately improving patient outcomes through precision oncology.

8 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BQBessi Qorri
Bessi Qorri
Reza Bayat MokhtariReza Bayat Mokhtari
Reza Bayat Mokhtari
WHWilliam W Harless
William W Harless
Myron R. SzewczukMyron R. Szewczuk
Myron R. Szewczuk
Resistance to chemotherapeutics and high metastatic rates contribute to the abysmal survival rate in patients with pancreatic cancer. An alternate approach for treating human pancreatic cancer involves repurposing the anti-inflammatory drug, aspirin (ASA), with oseltamivir phosphate (OP) in combination with the standard chemotherapeutic agent, gemcitabine (GEM). The question is whether treatment with ASA and OP can sensitize cancer cells to the cytotoxicity induced by GEM and limit the development of chemoresistance. To assess the key survival pathways critical for pancreatic cancer progression, we used the AlamarBlue cytotoxicity assay to determine the cell viability and combination index for the drug combinations, flow cytometric analysis of annexin V apoptosis assay to detect apoptotic and necrotic cells, fluorometric QCM™ chemotaxis migration assay to assess cellular migration, fluorometric extracellular matrix (ECM) cell adhesion array kit to assess the expression of the ECM proteins, scratch wound assay using the 96-well WoundMaker™, and the methylcellulose clonogenic assay to assess clonogenic potential. The combination of ASA and OP with GEM significantly upended MiaPaCa-2 and PANC-1 pancreatic cancer cell viability, clonogenic potential, expression of critical extracellular matrix proteins, migration, and promoted apoptosis. ASA in combination with OP significantly improves the effectiveness of GEM in the treatment of pancreatic cancer and disables key survival pathways critical to disease progression.

20 July 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
Reza Bayat MokhtariReza Bayat Mokhtari
Reza Bayat Mokhtari
BQBessi Qorri
Bessi Qorri
NBNarges Baluch
Narges Baluch
ASAngelo Sparaneo
Angelo Sparaneo
FFFederico Pio Fabrizio
Federico Pio Fabrizio
HYHerman Yeger
Herman Yeger
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Reza Bayat Mokhtari1,2,3, Bessi Qorri3, Narges Baluch4, Angelo Sparaneo5, Federico Pio Fabrizio5, Lucia Anna Muscarella5, Albina Tyker6, Sushil Kumar7, Hai-Ling Margaret Cheng8, Myron R. Szewczuk3, Bikul Das2,9,10 and Herman Yeger1 1 Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada 2 Department of Experimental Therapeutics, Thoreau Laboratory for Global Health, M2D2, University of Massachusetts, Lowell, MA, USA 3 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada 4 Department of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada 5 Laboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy 6 Department of Internal Medicine University of Chicago, Chicago, IL, USA 7 Q.P.S. Holdings LLC, Pencader Corporate Center, Newark, DE, USA 8 Institute of Biomedical Engineering, The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, University of Toronto, Toronto, Canada 9 Department of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India 10 Department of Immunology and Infectious Diseases, Forsyth Institute, Cambridge, MA, USA Correspondence to: Herman Yeger, email: hermie@sickkids.ca Reza Bayat Mokhtari, email: rbm7@queensu.ca Myron R. Szewczuk, email: szewczuk@queensu.ca Keywords: sulforaphane; acetazolamide; bronchial carcinoid tumors; serotonin; carbonic anhydrase Received: May 29, 2021 Accepted: June 14, 2021 Published: PUBLISHED_DATE Copyright: © 2021 Mokhtari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Objective: Aberrations in the PI3K/AKT/mTOR survival pathway in many cancers are the most common genomic abnormalities. The phytochemical and bioactive agent sulforaphane (SFN) has nutrigenomic potential in activating the expression of several cellular protective genes via the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 is primarily related to mechanisms of endogenous cellular defense and survival. The efficacy of SFN in combination with acetazolamide (AZ) was investigated in reducing typical H727 and atypical H720 BC survival, migration potential, and apoptosis in vitro and in vivo preclinical xenograft tissues. Materials and Methods: Microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 (M30, CCK18) CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR (qMSP), morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines. Results: Combining AZ+SFN reduced tumor cell survival compared to each agent alone, both in vitro and in vivo xenograft tissues. AZ+SFN targeted multiple pathways involved in cell cycle, serotonin secretion, survival, and growth pathways, highlighting its therapeutic approach. Both H727 and H720 cells were associated with induction of apoptosis, upregulation of the p21 cell cycle inhibitor, and downregulation of the PI3K/Akt/mTOR pathway, suggesting that the PI3K/Akt/mTOR pathway is a primary target of the AZ+SFN combination therapy. Conclusions: Combining SFN+AZ significantly inhibits the PI3K/Akt/mTOR pathway and significantly reducing 5-HT secretion in carcinoid syndrome. <!--x2o[4bb8ab8d]-->